ASTRODAILY NEWS

OCTOBER 22, 2020

President's Welcome Address Welcome to the 2020 ASTRO Annual Meeting

By Thomas I. Eichler MD. FASTRO. **ASTRO President**

WELCOME TO THE 62ND ANNUAL MEETING

of the American Society for Radiation Oncology, Global Oncology: Radiation Therapy in a Changing World! If we were following the original script, you would be reading this greeting while walking through the expansive Miami Beach Convention Center, dodging a sea of other attendees, en route to one of the proffered Master Classes, an Education or Scientific session or to the Presidential Symposium. That scenario ceased to be the norm over six months ago, as the annual celebration of our specialty migrated to an online format due to the coronavirus pandemic. If there is any good news here, it is that the Annual Meeting Steering Committee has had ample time to construct a diverse, interactive virtual meeting platform to provide both the quality and content - and value — that attendees have come to expect from ASTRO. I hope you will take full advantage of the numerous features that are available, literally at your fingertips, to navigate the meeting at your own pace and interact with our exhibitor partners in the Innovation Hub and with your colleagues. If you have not already done so, check out the allnew MyASTROApp from the App Store or Google Play. Let me take you on a high level tour of the meeting and give you some idea of what to expect.



ASTRO20 begins on Saturday, October 24, with the first day of the Practical Radiation Oncology (PRO) program and the first of four Cancer Breakthroughs sessions, expanded this year to include a number of our sister societies, and each will present the most important advances in their particular discipline. The meeting officially kicks off on Sunday morning with the Presidential Symposium. I chose The Global Clinic: Radiation Oncology in the 21st Century as the title of the Symposium and divided it into four one-hour segments, each progressively more granular. The program was developed by Dr. Norm Coleman, Dr. Surbhi Grover and me over the course of 18 months and is designed to examine the central issue of radiation oncology access disparity in lowand middle-income countries, including similar challenges for rural and urban America, and potential solutions going forward. Other Sunday highlights include Day 2 of the PRO program; an important socioeconomic update with the latest information on the RO Model; and the first of multiple ARRO Seminar sessions. Poster viewing and Storytelling sessions can be found daily, as well as multiple sessions devoted to global health


ARRO Annual Seminar adapts to new, virtual format with expanded programming

By Shauna R. Campbell, DO, ARRO **Executive Committee Chair, on behalf** of the ARRO Executive Committee

This year's Association of Residents in Radiation Oncology (ARRO) Annual Seminar has been adapted to a new expanded format, that offers more programming than ever before. The ARRO Annual Seminar begins on Sunday, October 25, with daily programming continuing through Wednesday, October 28. Also new this year, the ARRO Annual Seminar is included in the standard Annual Meeting registration and is open to all ASTRO Annual Meeting attendees. Seizing the opportunity to expand the program, given the flexibility with the virtual format, we attempted to make the meeting feel more personalized for residents. Mark your schedule to attend these exciting


Sunday, October 25

The ARRO Annual Seminar programming begins on Sunday with a popular topic: the job search. Speakers include Beth Beadle, MD; Lisa Kachnic, MD, FASTRO; ASTRO Chair Theodore DeWeese, MD, FASTRO; and Charles R. Thomas Jr., MD.



User Guide included inside!







STAGE 3 NSCLC AND THE POSSIBILITY FOR A CURE

With treatment advances, survival in unresectable Stage 3A•B•C NSCLC has improved to the point where achieving a cure may be possible for more of your patients^{1-3*}



Learn more at AZIOinPractice.com

CRT=chemoradiotherapy.

*As defined by 5-year overall survival rate for concurrent CRT, which has improved from 15% in 2010 to 32% in 2017.2-4

References: 1. Cheema PK, Rothenstein J, Melosky B, Brade A, Hirsh V. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. *Curr Oncol.* 2019;26(1):37-42. 2. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol.* 2010;28(13):2181-2190. 3. Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG Oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. *J Clin Oncol.* 2020;38(7):706-714. 4. Bradley JD, Hu C, Komaki RU, et al. Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +/- cetuximab for stage III NSCLC. *Int J Radiat Oncol Biol Phys.* 2017;99(2S)(suppl):S105.

What's Inside

President's Welcome Address 1
ARRO1
Social Champions1
Exhibit Hall4
Product Showcase5
Virtual Happy Hours7
ROI8
Storytelling9
RO-ILS11
2020 Abstract Awards Winners13
Advocacy Future Forecast15
Innovation Hub18
Street Talk21
Cancer Breakthroughs22
Corporate Ambassadors22
Gender Equity Community23
Promotional Sponsors23
Unrestricted Educational Grants Sponsors23
How To Guide25



Check out our 2020 Annual Meeting Exhibitor Directory!

ASTRO Daily News 2020

Publisher: Laura I. Thevenot Design/Production: Jaimie Hernandez

Editorial Director: Anna M. Arnone

Contributing Editors: Doriann Geller

Janet Hedrick Ksenija Kujundzic

Managing Editor: Diane Kean

Heather Ranels Colin Whitney



A Message from our CEO

Launching this virtual meeting has been an amazing undertaking, taking probably 10 times the staff time as holding the live meeting. Training faculty, getting all the presentations prerecorded, loading more than 2,000 posters, building the virtual booths and adding the content for all the screens that you will be clicking on to get more information has required ASTRO staff to develop new skills and work around the clock so everything on the platform will work smoothly for you. I would like to recognize the entire ASTRO staff who have pitched in and helped our Education and Meetings Division who

have taken the lead on this project. Also on my kudos list is our wonderful IT team who have been instrumental in working with the platform vendor on functionality and testing. They have done an outstanding job, which I know will be evident to you as you navigate through the presentations, Exhibit Hall, Zen Den, Networking Lounge and all the other activities we have in store for you.

I would also like to recognize our corporate partners who were willing to come with us on this journey. As you know, our exhibitors build massive booths and bring hundreds of staff to man their booths. We had a series of calls with them when the decision was made to move to virtual to turn the conversation from "we want a refund" to "what size booth with what features will best represent my company." Our Corporate Relations staff, who have long-term relationships with most of our exhibitors, held individual calls with each of them to explain the benefits of exhibiting on the platform. With all that hard work, we were able to retain 110 of our exhibitors, down from our usual 220, but still a very strong showing. For many of our exhibitors, this will be the first time that they will be able to connect with you, their customer, all year. I know they share my enthusiasm and are looking forward to interactions with you.

I also want to thank the faculty who have had to prerecord sessions, learn a lot of new technology and have worked collaboratively with staff to get sessions in on time so that we can load them all onto

As you have read, ASTRO has faced significant financial challenges this year. The Annual Meeting revenue drives our budget so we can provide member services and products such as guidelines, health policy, advocacy, science and research and education. Unfortunately, we have been unable to access any of the government relief funding for small businesses because of our non-profit tax status. It is unclear whether Congress and the Administration will be able to reach a compromise on another aid package, which does include assistance for our type of non-profit.

This is a year when, with the many challenges we are all facing personally and professionally, you really take stock in what is important. I feel honored and blessed to have led ASTRO over these many years. Our leaders and Board dedicate a great deal of time and energy to the Society, and I am so

I am hopeful that I can say see you in Chicago, but until then, I will be the avatar in the blue dress! Thank you for joining us on this journey.

Laura Theverst

Laura Thevenot, **ASTRO CEO**

Visit the Exhibit Hall

Our highly interactive and engaging Exhibit Hall, featuring more than 110 companies, allows attendees to visit exhibitors and learn about their products and services. Chat with booth representatives one-on-one or as a group, view product information, download marketing materials and even attend product demonstrations. Company representatives will be available during the hours listed below; however, you can visit the Exhibit Hall 24/7 and you may continue to contact exhibitors throughout the 30 days until Monday, November 30.



Hours of Operation:

Friday, October 23 - Thursday, October 29 10:00 a.m.- 5:00 p.m.



EXHIBIT HALL ONLY DAY

Given the busy Annual Meeting schedule, we recognize that it can be challenging to find enough time to visit all of your industry colleagues in the Exhibit Hall. That's why we have dedicated an entire day, Friday, October 23, as Exhibit Hall Only Day. This is a great opportunity to network with exhibitors to learn about the latest products and services in cancer treatment and care before Annual Meeting programming begins.



Stop by the Product Showcase for your first look at some of the latest products in the industry. Attendees can click on a specific product in the meeting platform to learn more.













COMPANY NAME:

Beijing HGPT Technology & Trade Co., Ltd

PRODUCT NAME:

ORI OA

COMPANY NAME:

Canon Medical Systems, USA

PRODUCT NAME:

Canon Medical Systems, USA

COMPANY NAME:

GT Medical Technologies Inc.

PRODUCT NAME:

GammaTile Therapy

COMPANY NAME:

Blue Earth Diagnostics Inc.

PRODUCT NAME:

Axumin® (fluciclovine F 18) Injection

COMPANY NAME:

Boston Scientific

PRODUCT NAME:

SpaceOAR Vue™ Hydrogel











COMPANY NAME: CDR Systems Inc.

PRODUCT NAME:

 $Freedom X^{\scriptscriptstyle\mathsf{TM}}\operatorname{-} Total\ Body\ Patient\ Immobilization$





COMPANY NAME:

GE Healthcare

PRODUCT NAME:

Discovery RT With MaxFOV Technology







Harmony



COMPANY NAME:

Mevion Medical Systems

PRODUCT NAME:

MEVION S250i Proton Therapy System®

COMPANY NAME:

MIM Software

PRODUCT NAME:

MIM Harmony™





COMPANY NAME:

Sensus Healthcare

PRODUCT NAME:

SRT-100 Vision™





COMPANY NAME:

Varian Medical Systems

PRODUCT NAME:

Ethos Therapy





COMPANY NAME:

Vision RT Ltd.

PRODUCT NAME:

Align RT

Best medical international

Best[™] Integrated Brachytherapy Solutions










TEAMBEST GLOBAL










First Century of Contributions of TeamBest Global in Healthcare Worldwide

A book to be published and distributed free of cost at the 2021 ASTRO Annual Meeting!

Huestis[™] Digital Simulator • GammaBeam[™] Systems • X-Beam[™] Radiosurgery • E-Beam[™] IORT • X-Beam[™] Multi-Energy Linac • 400 MeV Ion Rapid Cycling Medical Synchrotron (iRCMS)


















Best Medical International, Inc. 7643 Fullerton Road, Springfield, VA 22153 USA tel: 703 451 2378 www.besttotalsolutions.com www.theratronics.com www.teambest.com

Welcome Address continued from page 1

and global radiation oncology issues.

Master Classes have become another popular feature at recent meetings. This year, three such classes will be offered: Radiopharmaceutical Therapy; Professional Development—Leadership and Emotionally Intelligent Communication; and Cannabis in Cancer Care. Please take note that these are ticketed events, as are the Live SA-CME, eContouring Sessions and the Grant Writing Workshop.

Our two Keynote speakers will be addressing timely, but very different, topics. At 8:45 a.m. Eastern time on Monday, Dr. Felicia Knaul, director of the University of Miami's Institute for Advanced Study of the Americas, will present our first Keynote Address, Closing the Global Cancer Divide AND Strengthening Health Systems: Interwoven Opportunities. Dr. Knaul is an internationally renowned health economist and an expert in Latin American health systems, previously serving as director for the Harvard Global Equity Initiative. Following her address, she will participate in a fireside chat with Dr. Mary Gospodarowicz. Our second Keynote, A Conversation About Race with Professor Ibram X. Kendi, will begin at 3:00 p.m. Monday. Dr. Kendi is the author of the New York Times bestseller "How to Be an Antiracist" and is the director of the Center for Antiracist Research at Boston University. He will be interviewed by our colleague Dr. Curt Deville.

My Presidential Address late Monday afternoon will take you on a tour of the nearly 125-year history of therapeutic radiation and the evolution

of ASTRO entitled Then, Now and...What Next? I hope you'll tune in and then join me Monday evening for the virtual Happy Hour!

There is the usual wide array of Scientific and Education sessions from which to choose. Once that day's content is released, it will be available until November 30 to allow attendees to attend conflicting sessions on their own schedule. More than 200 CME credit hour opportunities are available, far more than the usual 35-40 hours for a live meeting. I would like to call your attention to the Plenary Session on Monday from 1:15 p.m. to 2:30 p.m.; the Late-breaking Abstracts session on Tuesday afternoon beginning at 3:00 p.m. with late-breaking COVID-19 abstracts at 4:00 p.m.; and the Clinical Trials session on Wednesday at 10:15 a.m. In addition, there will be a special coronavirus session on Wednesday at 2:30 p.m., featuring the director of the National Institute of Allergy and Infectious Diseases and White House Coronavirus Task Force member, Dr. Anthony Fauci, Dr. Patrice Harris, a psychiatrist and immediate past president of the American Medical Association, and Dr. Amalia Del Riego Abreu, chief of the Health Services and Access Unit with the Pan American Health Organization/World Health Organization.

Finally, please pay some heed to a longstanding initiative inextricably linked to the past, present and future of our specialty: the Radiation Oncology Institute (ROI). The Annual Meeting is the trigger point for many members to donate to this critically important entity. The ROI uses the meeting to engage potential donors face-to-face to further their mission to foster and fund radiotherapyrelated research. Donations to the ROI may be made by anyone, and you can donate at the ROI booth, using links found on the meeting virtual platform or at www.roinstitute.org/donate.

And so, my friends, while the pandemic may have robbed us of the sheer joy of being together in South Beach, don't let your enthusiasm for this Annual Meeting be dampened. As the Roman poet Horace famously said, "Carpe diem." Seize the day. Make the most of this moment. There is no other organization that has put together a virtual medical meeting of this magnitude with such diverse and ambitious content. Take the time to explore all of the various features this platform offers, all at your own pace. I am deeply appreciative of your commitment to ASTRO and to the patients we serve. Enjoy the meeting! 🗛

Connect with attendees.







We've all done it during the past few months, why not do it during the ASTRO Annual Meeting? That's right, ASTRO has planned a virtual Happy Hour where you can connect with old friends and meet new friends while enjoying some friendly competition, taking in some culture or enjoying a wine tasting. Join us on Monday, October 26, at 5:30 p.m. Eastern time in the Networking Lounge, where you can select a happy hour experience that interests you. Choose from "Gray Pardy," "Pub Trivia," a museum tour or a wine tasting, or use this time to connect with your industry colleagues to learn about the latest products and services in cancer treatment and care. Happy Hour will kick off with a toast from our very own ASTRO President Dr. Eichler!

Here's more information to help you decide which experience to choose:

ASTRO's version of the hit game show Jeopardy! There will be five RadOnc-themed categories and five questions in each category. Participants will join a team to compete against each other. The game will be hosted by a RadOnc colleague, "Alexa" Trebek!

Pub Trivia

Grab your favorite bubbly beverage to join us in a battle for who has the greatest knowledge of trivia!

Museum Tours

What can be better than taking a trip through some of the world's greatest collections in these virtual museum and gallery tours — all from the comfort of your home? Options will include:

- The Smithsonian National Museum of Natural History located in Washington, D.C., features a narrated tour that houses a collection of 145 million specimens and artifacts.
- Explore the Guggenheim, Bilbao and its extensive collection of modern art. Some of the more notable artworks include "Untitled" by Mark Rothko and "Nine Discourses on Commodus" by Cy

Twombly. Its most iconic piece, "Maman" by Louise Bourgeois, stands just outside the museum.

- The Vatican Museum, aptly called "the Museum of Museums," not only houses extensive collections of art, archaeology and ethno-anthropology gathered by the popes over the centuries, but also contains some of the Apostolic Palace's most extraordinary and artistically significant rooms.
- The Musée d'Orsay is located in the center of Paris on the banks of the Seine and opposite the Tuileries Gardens. The museum was installed in the former Orsay railway station, originally built for the Universal Exhibition of 1900, and displays collections of art from the period 1848 - 1914.

Virtual Vineyard

Turn your living room into a tasting room with our Virtual Vineyard. Sit back and relax from the comfort of your home while our wine experts at Barboursville Vineyards guide you, your friends and family through a fun and interactive tasting. Featured wines include: Vermentino Reserve 2018, Allegrante Rose 2019 and Cabernet Franc Reserve 2018.

Visit the Radiation Oncology Institute Booth Get to know your research foundation

By Janet Hedrick, Director of Development, ROI

THE RADIATION ONCOLOGY INSTITUTE (ROI).

ASTRO's Research Foundation, will have an exhibit booth at the ASTRO Annual Meeting. We invite you to stop by and get to know your research foundation during the Exhibit Hall hours, Friday, October 23, through Thursday, October 29, from 10:00 a.m. to 5:00 p.m. Eastern time daily.

While we cannot offer you a cup of coffee or snacks at the booth, as we have in the past, you still can chat with members of the ROI Board of Trustees and the ROI staff to learn why your support of the ROI is important for research that has an impact on patient outcomes. Discover how the ROI puts gifts to work by watching videos of the 2020 ROI award winners who are conducting research to enhance diversity, inclusion and health equity. You can also download — and talk with us about — the current request for proposal that will result in new ROI grants focused on biomarkers for radiation oncology in spring 2021.

In addition, the booth provides a list of donors to the ROI and quotes from donors about what motivates them to give. You can see who has given this year and who has made leadership gifts in the past — and why these ASTRO members support research in radiation oncology.

Other ROI highlights at the ASTRO Annual Meeting include:

2020 Publication Award



The ROI is pleased to honor Robert T. Dess, MD, assistant professor at the University of Michigan, as the winner of the 2020 Publication Award. Dr. Dess is the lead author of the article "Association of Presalvage Radiotherapy PSA Levels After Prostatectomy with Outcomes of Long-term Antiandrogen Therapy in

Men with Prostate Cancer," which was published in JAMA Oncology in March. Many excellent manuscripts were nominated, and the ROI is recognizing two researchers with Honorable Mentions: Rachel B. Jimenez, MD, assistant professor at Massachusetts General Hospital, for the article "Phase II Study of Proton Beam Radiation Therapy for Patients with Breast Cancer Requiring Regional Nodal Irradiation," and Jacob Miller, MD, resident physician at Stanford University for the article "Cost-Effectiveness and Quality-Adjusted Survival of Watch and Wait After Complete Response to Chemoradiotherapy for Rectal Cancer." Join the ROI in congratulating these outstanding early career researchers!




Step Up for Research

While we will not be gathering for the 5K Run for the Future to Benefit the ROI this year, we are conducting a campaign to replace the revenue that the ROI would have garnered from the race. The campaign is called Step Up for Research, and the dollars contributed will be used to advance research in radiation oncology. We will miss seeing everyone bright and early on Monday morning for the race, but you can participate in Step Up for Research at the ROI virtual booth, where you can make your online contribution.

Financial Planning Session

Russell LaGreca, CFP, CIMA, CRPS, vice president of Morgan Stanley's Wealth Management Division, will present the session, Financial Planning: The SECURE Act and Its Impact on Your Future. The pre-recorded on Demand session will be released on Monday, October 26. Mr. LaGreca will be available at the ROI booth for one-on-one meetings with attendees on Monday, October 26, from 11:00 a.m. to 12:00 p.m., on Tuesday, October 27, from I:00 p.m. to 3:00 p.m., and on Wednesday, October 28, from 10:00 a.m. to 12:00 p.m.

Please note, Mr. LaGreca is not affiliated with nor endorsed by ASTRO or ROI. His views and advice belong to him and are not the views or advice of ASTRO or ROI.





As a white physician, it is easy to overlook the struggles that our patients of color experience daily. After the death of George Floyd, I decided that I had to start listening to my patients closely to learn what they go through and to make sure that I am not contributing to their pain. Once I asked the question, I started hearing heartbreaking stories about how my Black patients are treated in a town where health care providers are largely white. Mainly, I heard that our Black patients didn't feel like they were seen. Thankfully, I heard universally that the radiation center had been a safe haven for them, and they all felt appreciated for who they were and not judged by their color. Three patients told me that they were ready to give up on their cancer because they were so disheartened. My staff, with their wonderfully embracing personalities, had made the difference for these patients. However, we had failed to notice how the rest of the medical community was ignoring the needs of these patients and had failed to make sure those non-radiation needs were met. I have vowed to not let this happen again.

Sometimes we forget how much power we have in the lives of our patients. I encourage everyone to ask the uncomfortable questions and be ready to hear what might be some uncomfortable truths. Be the bright light of encouragement for each and every patient. ❖

LIVE STORYTELLING SESSIONS ARE **SCHEDULED FOR:**

- Saturday, October 24, 9:00 a.m. 10:30 a.m., Global and Domestic Prostate Cancer
- Sunday, October 25, 3:00 p.m. 4:30 p.m., Virtual Medical Education, U.S. Oncology Response to COVID-19, and Northern Italy's COVID Response
- Tuesday, October 27, 10:30 a.m. 12:00 p.m., Radiation Oncology in the Time of COVID;
- Tuesday, October 27, 3:00 p.m. 4:30 p.m., Overcoming Barriers to Radiation Oncology Access in Low-resource Environments
- Wednesday, October 28, 9:00 a.m. 10:00 a.m., ASTRO's COVID-19 Survey Results

"It hurts most right here, Gavin," my patient remarked, pointing to a rather sizable lump on his waist. "And in my right chest too. I can't even swallow."

I looked him over. His body reminded me of a kite, with rigid skin pulled taut over harsh and angular bones. The metastases were scattered everywhere — too numerous to count. Sensing the look of consternation on the faces of his wife and daughter, I knew it was time for an earnest conversation. As I left the room to fetch a chair, I could hear the stentorian cough of my other patient boom throughout the ward corridors.

This was my first week on 8 West, the hospital's inpatient oncology wing. Everyone in my medical school class, even many of the residents, knew that I was interested in this field of medicine. The truth is that I had always found cancer, in all its multifaceted complexity, to be the most human disease. Human in its biology: the idea that cancer stems from a corruption of the very genes responsible for our phylogeny and existence, accentuating a delicate interplay between cellular stability and mutability. Human in its emotional impact: how a diagnosis of cancer brings the significance of our actions and the preciousness of our lives into sharp relief. And lastly, human in its universality: the notion that everyone who lives on this planet will inevitably be affected by cancer as friends, family members and, perhaps, even we ourselves eventually succumb to the disease. For someone who pursued medicine to better understand and elevate the human experience, the attraction to this field was innate. From the micro to macro level, cancer is the common thread that undergirds a shared narrative: where we came from, how we got here, how we live and what is important to us.

All of these thoughts swirled in my mind as I pulled the chair up next to my patient and his family. He was here to enroll in a new clinical trial for bladder cancer. In the meantime, he was in extreme physical pain, unable to eat, severely nauseated and plagued by persistent hiccups. "There are things we can do to make you more comfortable and help with your symptoms," I averred. "Have you ever heard of radiation therapy?"

For coupled with my thoughts on cancer the disease was always an inclination toward the pragmatic and procedural — an attraction to targeted techniques, technology and tangible results. I had done research in radiation oncology at the end of my first year of medical school and relished both the broad scope of malignancies treated with radiation and the novel means of doing so. Here was an intellectually challenging, research-driven field that also afforded substantive relationships and interactions with patients. Most importantly, radiation could make a significant difference in people's lives; my patient's case seemed like the perfect opportunity. I decided to broach the idea of palliative radiation to my attending. She agreed.

The end of his story was an affirming one in the utmost sense. Over the subsequent weeks, I watched the once-prominent pelvic and sternal nodules wane and nausea and hiccups yield to a stable appetite. "The pain is a lot less, too." Buoyed by the hope of the new clinical trial and bolstered by the effects of the radiation, his improvement reinforced my attraction to a field that could clearly do so much to better the lives of its patients.

I carry this story around with me as a constant reminder that, in the end, all of our endeavors in this specialty come down to people. Amid the Kaplan-Meier curves, fractionation regimens, RTOG trials and monitor units calculations, the core of the practice of medicine remains a heartfelt and therapeutic exchange between two individuals. I have always had a desire to contribute to the field of radiation oncology in manifold ways: as a scholar exploring the intersection of evolving medical and radiation domains and an educator amid a spirit of innovation, sense of collegiality and didactic impetus offered by a professional career in an academic setting. But the most fundamental is on an intimate level, by bringing a genuine sense of care and compassion to all my patients. In these most trying of times, we must strive to never lose sight of this raison d'être of the physician. ❖



Best medical international

Best[™] Integrated Brachytherapy Solutions









Best Medical is the <u>only</u> company that makes custom seeds & strands to your exact specifications — shipped within 24 hours, 7 days a week, sterile & non-sterile!








First Century of Contributions of TeamBest Global in Healthcare Worldwide

A book to be published and distributed free of cost at the 2021 ASTRO Annual Meeting!







Best Medical International, Inc. 7643 Fullerton Road, Springfield, VA 22153 USA tel: 703 451 2378 800 336 4970 www.besttotalsolutions.com www.teambest.com

ASTRO Quality Efforts Support Requirements of the New RO Model

By Ksenija Kujundzic, Quality Improvement Manager

The new radiation oncology alternative payment model, known as the RO Model, is packed with various quality components and requirements in an effort to ensure high quality care while reducing cost. Some attention has been geared toward the new Aggregate Quality Score (AQS), which in 2021, the first year of the program, will be determined by:

- performance on three quality measures (plan of care for pain, depression screening and advance care plan) in comparison to those measures' benchmarks;
- reporting of one quality measure on treatment summary communication; and
- reporting of clinical data elements for five specific disease sites.

One practical impact of the AQS, then, is that it is associated with payment. In an effort to incentivize quality, there is an initial 2% financial withholding for professional and dual (technical and professional) participants that can be earned back based on their AQS. However, there are other quality requirements associated with the RO Model that have received less attention and where ASTRO programs can help.

All technical and dual participants will be required to attest annually to active participation in a federally listed patient safety organization (PSO). Since 2013, ASTRO has been contracted

with Clarity PSO, listed by the Agency for Healthcare Research and Quality (AHRQ), to provide PSO services to interested practices for RO-ILS: Radiation Oncology Incident Learning System®. Therefore, participation in RO-ILS will meet this requirement. ASTRO offers the program completely free of charge, thanks to cosponsorship with AAPM, and financial support from Varian, the American Society of Radiologic Technologists (ASRT), the American Association of Medical Dosimetrists (AAMD) and Sun Nuclear Corporation. Prior to participating in RO-ILS, practices must enroll in the program. A practice must first contract with Clarity in order to establish the protections afforded by the Patient Safety and Quality Improvement Act of 2005, after which Clarity onboards the practice and the practice implements the program. There are numerous reasons why practices should participate in RO-ILS, most important is that it helps improve the quality of care for patients and makes processes safer. RO-ILS also helps improve the safety culture, encourages better communication and helps to build a collaborative team dedicated to assessing ways to increase effectiveness and efficiencies. Other concrete benefits include built-in analysis tools, education from the national database and associated legal protections. To learn more about RO-ILS, contact <u>roils@astro.org</u>.

Additionally, participants will be required to perform and document peer review in the

medical record for 50% of new patients in the first performance year, preferably before starting treatment, but in all cases before 25% of the total prescribed dose has been delivered and within two weeks of starting treatment. Stemming from ASTRO's Rural Task Force, ASTRO developed a free Peer-to-Peer Match program to help connect interested individuals to peer review each other's cases. It is a user-driven, online tool hosted on ROhub that allows enrolled participants to search, using specified criteria, for other interested individuals to assist in evaluating patient cases and treatment plans. Participants will communicate outside the platform using their own communication vehicles to establish the parameters of the relationship and review cases. While the RO Model has a low volume opt-out option, it does not currently include a good faith exemption for small or rural practices, so be sure to utilize the Peer-to-Peer Match program to establish the necessary relationships to meet this requirement. To learn more about this program, contact communications@astro.org.

ASTRO continues to advocate for changes to the RO Model, including urging the Centers for Medicare and Medicaid Services to delay the model start date of January 1, 2021, and reduce the discount factors. To learn more, read <u>ASTRO's summary of the final rule</u> and keep an eye out for future education and updates in the weekly ASTROgram.



Visit our virtual booth at ASTRO




Visit keytruda.com/hcp to learn more about KEYTRUDA:

- Approved indications
- Resources for health care professionals
- The Merck Access Program
- KEY+YOU Support Program for patients



Congratulations to the 2020 Abstract Award Winners!









International Development Abstract Award

This grant is designed to foster continuing medical education, assist in career development and help to establish relationships with leading ASTRO members who may serve as scientific mentors to each recipient. One award of \$4,000 will be used to support a radiation oncologist in a developing country to attend the ASTRO Annual Meeting and to spend additional time at a comprehensive cancer center within the United States. The award also includes a certificate of recognition. It is awarded to the highest-rated abstract submitted by those who applied and provided their CV and letter of recommendation.

Dawei Chen, MD, PhD, Shangong University

Oral Scientific Session SS 32 – Biology 09 ONDEMAND

Abstract Title: SHP-2 and PDL1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD1-Resistant Model of Non-Small-Cell-Lung Cancer

Resident Clinical/Basic Science Award

This award is designed to promote clinical research by young scientists. The award is granted to the top three resident authors of significant abstracts in biology, clinical practice and physics. The award includes a \$1,500 honorarium, a trophy of recognition and complimentary registration to the Annual Meeting.

Justin Oh, MD - BC Cancer Agency, Vancouver (Clinical)

Scientific Session 22 - GU 04 ONDEMAND

Abstract Title: An Updated Analysis of Survival Endpoints for ASCENDE-RT, a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

Alexander Augustyn, MD, PhD - University of Texas MD Anderson Cancer Center (Biology) Scientific Session SS 38 - Biology 11 onDEMAND

Abstract Title: Relationship Between Buccal Microbiome Diversity and Overall Survival in Locally Advanced NSCLC Patients Treated with Chemoradiation and Immunotherapy

James Janopaul-Naylor, MD - Emory University (Physics) Scientific Session SS 02 – Physics 01 Best of Physics OnDEMAND

Abstract Title: Synthetic CT-aided Online CBCT Multi-organ Segmentation for CBCT-guided Adaptive Radiotherapy of Pancreatic Cancer

Nurse Abstract Award

This award is designed to promote clinical research among radiation oncology nurses. Two awards of \$1,000 will be presented to the highest rated abstracts with a nursing designation. The winners receive a certificate of recognition and complimentary registration to the Annual Meeting.

- Kathleen Doughtie, DNP, APRN, WHNP MD Anderson Cancer Center
- Heejin Kim, DNP, AOCNP University of Michigan







Continued on next page






























Basic/Translational Science Award

This award is designed to encourage participation in the ASTRO Annual Meeting by basic and translational scientists. Up to 12 awards are given to applicants having the highest-rated abstracts in clinical, biology or physics categories. Four awards are given in each category to a mix of junior and senior investigators. The award includes a \$1,000 honorarium, a certificate of recognition and a complimentary registration to the Annual Meeting.

Clinical

- **Daan Spoor, MSc** University Medical Center Groningen (Junior Investigator)
- **Douglas Castro, MD** AC Camargo Cancer Center (Senior Investigator)

Radiation Physics

- **Benjamin Geraghty, PhD** Sunnybrook Research Institute (Junior Investigator)
- Mustafa Syed, MD Heidelberg University Hospital (Junior Investigator)

Radiation and Cancer Biology

- Suchit Patel, MD, PhD Mary Bird Perkins Cancer Center (Junior Investigator)
- William Chen, MD University of California San Francisco (Junior Investigator)
- **Min Li, MD, PhD** Rujin Hospital, Shanghai Jiaotong University School of Medicine (Senior Investigator)

Resident Recognition Awards

This award recognizes the highest-rated abstracts submitted by residents and accepted as a Digital Poster presenter or as an oral session presenter in the Quick Pitch sessions. The award is granted to the top three resident authors of significant abstracts in each category: biology, clinical practice and physics and up to nine trophies are awarded.

Resident Quick Pitch Recognition Award

- Archya Dasgupta, MD Sunnybrook Health Sciences Centre (Biology)
- Shwetha Manjunath, MD Hospital of the University of Pennsylvania (Clinical)
- Michael Prusator, PhD Washington University School of Medicine, St. Louis (Physics)

Resident Poster Viewing Recognition Award

Radiation and Cancer Biology

- Zachary Moore, MD, PhD Memorial Sloan Kettering Cancer Center
- Jason Beckta, MD, PhD Yale University
- **Steven Seyedin, MD** *University of Iowa Hospital and Clinics*

Radiation Physics

- **Kevin Lee, MD, PhD** University of Alabama Birmingham
- Hesham Elhalawani, MD, MS Cleveland Clinic
- **Hui Lin, PhD** University of Pennsylvania

Clinical

- Pamela Samson, MD Washington University
- Vishesh Agrawal, MD New York-Presbyterian Weill Cornell Medical Center
- Steven Allen, MD, PhD University of Michigan



2020 HAS BEEN A YEAR FULL OF TWISTS AND

TURNS, and ASTRO's Advocacy team has readily adapted as many issues, old and new, took on altered appearances due to the COVID-19 public health emergency. The advocacy team worked tirelessly at the outset of the pandemic to ensure that radiation oncology providers and their goals were part of the conversation in Washington, as Congress and federal agencies reacted to shore up the American health care system. This fall, ASTRO's Advocacy team has found itself in the throes of responding to the RO Model final rule that establishes an alternative payment model for radiation oncology practices. The final rule has significant flaws and does not begin to address the issues that ASTRO expressed in response to the proposed rule that was issued in July 2019. Now, as we look to the future, ASTRO's outgoing Government Relations Council Chair, Ronald Ennis, MD, FASTRO, helps provide context to the journey ahead of us as we address the shortcomings associated with the RO Model and fight to fix prior authorization, which has unfortunately become more problematic during the pandemic.

What works in the RO Model final rule?

Ronald Ennis (RE): Sadly, not enough. ASTRO had advocated for an alternative payment model that established rate stability for radiation oncology practices. The RO Model final rule does not achieve that. The Centers for Medicare and Medicaid Services (CMS) failed to appropriately address the concerns voiced by both ASTRO and Congress. In what was supposed to be a model test, the RO Model acts instead as a payment cut that places undue burden on providers that ultimately will result in access to care issues for patients. Notably, CMS failed to account for the shortcomings in the payment methodology that will result in significant cuts to participating practices. Compounding those cuts is the fact that CMS proposes a 10% cut to the Conversion Factor in the Medicare Physician Fee Schedule (MPFS), which acts as a rate update under the model.

Additionally, the January 1, 2021, launch date disregards ASTRO's concerns regarding the impact of the COVID-19 public health emergency. CMS also did not take steps to support and reward the highest quality and most efficient care for patients. By issuing marginal .25 reductions to the discount factors, CMS ensures further financial stress will be piled onto radiation oncology providers in an environment in which many providers are already strained.

Where do we go from here with the RO Model?

RE: Primarily, we must continue to urge Congress or CMS to take action to delay the launch date of the Model and reduce the discount factor cuts. Once these actions are taken, our focus should shift back to working with CMS to provide insight to provider experience with implementation of the new Model. Most importantly, we should focus on giving an accurate view to the burdens of participation and monitoring requirements and continue pushing for the most accurate base rates and updates in the payment methodology. This is the time for all members to get involved and push for change.

You mentioned the impact of the 2021 **Medicare Physician Fee Schedule proposed** cuts on the RO Model. Can you tell us a little more about that?

RE: The biggest concern stemming from the 2021 Medicare Physician Fee Schedule proposed rule is, obviously, the proposed payment cuts tied to new evaluation and management (E/M) codes. These cuts, on top of the COVID-19 triggered revenue losses experienced across the house of medicine, are worrisome, especially since Congress likely will need to act legislatively to address them. Practices participating inside the RO Model and those outside the RO Model will be significantly impacted. We'll keep up the fight to get Congress or CMS to waive the cuts before they are implemented on January 1, 2021, but again, we need ASTRO members to contact their representatives to drive this home.

Shifting to prior authorization, how has the fight to fix prior auth changed this year?

RE: The COVID-19 public health emergency should give Congress and CMS new perspective on the burden that prior authorization has on both patients and providers. ASTRO data shows that the public health emergency has led to delays to ideal treatment start dates and, therefore, the worsening of patient conditions. Layered on top of this is the added delay caused by restrictive prior authorization policies, which take up precious time. This makes the need to fix prior authorization requirements and stop their burden on patient access to care much more urgent.

One silver lining in this cloud of a year is the significant momentum that has grown in Congress for the adoption of H.R. 3107, the bipartisan Improving Seniors' Timely Access to Care Act, which has hundreds of supporters. The hope is that Congress can finally take the first step to combat those requirements that delay access to critical care and restrict radiation oncologists from exercising clinical judgement. This is by no means enough, but it would give ASTRO more footing to push for more widespread prior authorization fixes.

For more information on the **RO Model and** MIPS 2021, be sure to check out the **Quality Payment** Program: RO Model and MIPS 2021 Live session in the T.J. Eichler Theater on October 25, 10:30 a.m. – 12:00 p.m. Eastern time.

For more information on the 2021 MPFS proposed rule, be sure to check out the 2021 Radiation **Oncology Coding** and Coverage **Update** Live session in the T.J. Eichler Theater on October 26, 10:00 a.m. – 11:30 a.m. Eastern time.





STAGE 3 NSCLC AND THE POSSIBILITY FOR A CURE

With treatment advances, survival in unresectable Stage 3A•B•C NSCLC has improved to the point where achieving a cure may be possible for more of your patients^{1-3*}



Learn more at AZIOinPractice.com

CRT=chemoradiotherapy.

*As defined by 5-year overall survival rate for concurrent CRT, which has improved from 15% in 2010 to 32% in 2017.2-4

References: 1. Cheema PK, Rothenstein J, Melosky B, Brade A, Hirsh V. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. *Curr Oncol.* 2019;26(1):37-42. 2. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol.* 2010;28(13):2181-2190. 3. Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG Oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. *J Clin Oncol.* 2020;38(7):706-714. 4. Bradley JD, Hu C, Komaki RU, et al. Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +/- cetuximab for stage III NSCLC. *Int J Radiat Oncol Biol Phys.* 2017;99(2S)(suppl):S105.



INNOVATION HUB

Sponsored in part by Varian Medical Systems and ViewRay Inc.

* Schedule as of September 28, 2020.
Please visit www.astro.org/conferenceplanner for updated information.

In addition to the popular Industry-Expert Theaters and Industry Satellite Symposia, we have added Main Stage Presentations and 15-minute Lunchtime Product Demonstrations from featured exhibitors. New for this year, the Main Stage will host CEOs and CMOs of technology companies, designers, startups, key opinion leaders and business strategists. Additionally, attendees can get the latest information from exhibitors on their products during 15-minute Lunchtime Product Demonstrations. Please refer to the website for the most current schedule and session descriptions. All times listed are Eastern time.

PRODUCT DEMONSTRATIONS					
Sum day Octob on 25	12:00 p.m. – 12:15 p.m.	ViewRay, Inc.	Innovation in Action: What's next for MRIdian		
Sunday, October 25	12:15 p.m. – 12:30 p.m.	Philips Healthcare	Pinnacle Evolution		
	11:00 a.m. – 11: 15 a.m.	Qfix	Qfix Encompass™ 15-Channel Head Coil on Siemens 3T MR Scanner		
	11:15 a.m. – 11:30 a.m.	CIVCO Radiotherapy	CIVCO Solstice™ SRS Immobilization System		
	11:30 a.m. – 11:45 a.m.	IBA (Ion Beam Applications)	IBA Proton Therapy		
Manday October 26	11:45 a.m. – 12:00 p.m.	Sun Nuclear Corporation	SunCHECK		
Monday, October 26	12:00 p.m. – 12:15 p.m.	Varian Medical Systems	Ethos™ Therapy		
	12:15 p.m. – 12:30 p.m.	Philips Healthcare	IntelliSpace Radiation Oncology		
	12:30 p.m. – 12:45 p.m.	IBA (Ion Beam Applications)	IBA Dosimetry Product		
	12:45 p.m. – 1:00 p.m.	Elekta	The Power of Personalized: How Elekta is fighting cancer through new Digital Solutions		
	11:00 a.m. – 11:15 a.m.	Brainlab	Brainlab Elements 3.0		
	11:15 a.m. – 11:30 a.m.	Siemens Healthineers	SOMATOM go.Sim & SOMATOM go.Open Pro		
	11:30 a.m 11:45 a.m.	ViewRay, Inc.	Innovation in Action: Real-Time, On-Table Adaptive		
Tuesday, October 27	11:45 a.m. – 12:00 p.m.	Mevion Medical Systems	MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning (PBS)		
	12:00 p.m. – 12:15 p.m.	Elekta	ProKnow		
	12:15 p.m. – 12:30 p.m.	Varian Medical Systems	IDENTIFY		
	12:30 p.m. – 12:45 p.m.	Sun Nuclear Corporation	MultiMet Winston-Lutz Cube		
Wednesday, October 28	11:00 a.m. – 11:15 a.m.	Brainlab	Brainlab Elements 3.0		

INDUSTRY-EXPERT THEATERS				
Monday, October 26 12:00 p.m. – 1:00 p.m.	Novocure Inc.	Presentation Title: Tumor Treating Fields: Translating Science into Practice Objectives: • Provide an overview of the mechanism of action of Tumor Treating Fields (TTFields) and evidence for activity in tumor cells • Share clinical trial experience with TTFields supporting its application in glioblastoma and malignant pleural mesothelioma (MPM) Speakers: • Dr. Pavan Jhaveri, Smith Radiation Oncology, Baylor College of Medicine • Dr. Samir P. Kanani, George Washington University		
Tuesday, October 27 11:00 a.m. – 12:00 p.m.	ViewRay, Inc.	Presentation Title: Maximizing Clinical Value of MRIdian – Dana-Farber/Brigham Women's Cancer Center		
Tuesday, October 27 12:00 p.m. – 1:00 p.m.	Janssen Biotech, Inc.	Presentation Title: ERLEADA: TITAN and New Data for SPARTAN Final Analysis Speakers: Dr. Steven Finkelstein, Florida Cancer Affiliates (The US Oncology Network) Dr. David Crawford, University of San Diego California This session will not be recorded and will only be available during the date and time listed.		
Wednesday, October 28 11:00 a.m. – 12:00 p.m. Presentation Title: TUKYSA* (tucatinib): A Treatment Option for Patients with HER2+ Metastatic Breast Cancer (MBC) Speaker: Rebecca Lynn Moroose, MD This session will not be recorded and will only be available during the date and time listed.				
Wednesday, October 28 11:00 a.m 12:00 p.m.	ASTRO-Expert Theater	Session Title: Code Development and Valuation: What Radiation Oncology Industry Stakeholders Need to Know Radiation Oncology is a dynamic and innovative field. Industry stakeholders frequently come to ASTRO with questions regarding coding and valuation for new technologies and services. This is an opportunity to hear from ASTRO's experts about the process, what's involved and why collaboration is critical. ASTRO Experts: • Amar Rewari, MD, MBA – Dr. Rewari serves as a member of ASTRO's Code Development and Valuation Committee. He is also ASTRO's RUC Alternate Advisor. • Catheryn Yashar, MD – Dr. Yashar serves as a member of ASTRO's Code Development and Valuation Committee. She is also ASTRO's CPT Alternate Advisor. • Bryan Hull, Esq., MPH – Mr. Hull is ASTRO's Assistant Director of Health Policy. He serves as the staff liaison to the Code Development and Valuation Committee, as well as the key staff point person for ASTRO's CPT and RUC activities.		

ASTRO has reviewed and approved these symposia for presentation. These symposia represent the content and views of the supporters and are not part of the official ASTRO Annual Meeting. All times listed are Eastern time.

		NON-CME INFORMATIONAL/EDUCATIONAL PROGRAM		
Saturday,	5:00 p.m. 5:30 p.m.	TARGIT-A Survival and Local Control Outcomes as a Single IORT Fraction-Randomized Controlled Phase III Long Term Results This is a Non-CME informational activity designed for radiation oncologists, medical physicists, surgical oncologists, breast surgeons, hospital		
October 24 5:00 p.m 5:30 p.m.		administrators, radiotherapy administrators, radiotherapists, nurse navigators and cancer program administrators. No CME is offered for this program.		
		This activity is hosted by Carl Ziess Meditec Inc.		
		INDUSTRY SATELLITE SYMPOSIA		
Sunday, October 25	5:00 p.m. – 6:30 p.m.	Optimizing Care in Lung Cancer: Current and Emerging Biomarkers for Immuno-Oncology Joint Accreditation Statement: In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Physician Continuing Medical Education: CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity is supported by an educational grant from Merck Sharp & Dohme Corp.		
Sunday, October 25	5:45 p.m. – 6:45 p.m.	Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancers: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians. CME Credits: The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For more information and to register, please visit PeerView.com/RadOnc2020. This activity is supported through an educational grant from Bristol Myers Squibb.		
Tuesday, October 27	5:30 p.m. – 6:30 p.m.	Modernizing Your Radiation Oncology Practice With Tumor Treating Fields and Other Novel Multimodal Strategies: Understanding the Science, Evidence and Practical Aspects Across a Range of Solid Tumors Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians. CME Credits: The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit**. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For more information or to register, please visit PeerView.com/RadOnc20. This activity is supported by an educational grant from Novocure.		



All events will take place in the Innovation Hub. On the virtual platform, navigation to the Innovation Hub can be found from the Main Lobby or via the Exhibit Hall.

MAIN STAGE PRESENTATIONS				
Sunday, October 25	4:30 p.m. – 4:50 p.m.	4:30 p.m. – 4:50 p.m. TibaRay		
	9:45 a.m. – 10:05 a.m.	Leo Cancer Care Ltd.		
	10:10 a.m. – 10:30 a.m.	Cybrexa		
	10:30 a.m. – 11:30 a.m.	ViewRay, Inc.		
Monday, October 26	11:30 a.m. – 11:50 a.m.	Concure Oncology		
	12:00 p.m. – 12:20 p.m.	bridge7		
	12:30 p.m. – 1:00 p.m.	Elekta		
	3:45 p.m. – 4:05 p.m.	Oncora Medical		
	10:15 a.m. – 10:25 a.m.	Supportive Therapeutics		
	10:30 a.m. – 10:50 a.m.	HPEC		
Tuesday, October 27	12:00 p.m. – 12:30 p.m.	Novocure Inc.		
	2:00 p.m. – 3:00 p.m.	Funding		
	4:15 p.m. – 4:45 p.m.	TheraPanacea		
	12:00 p.m. – 1:00 p.m.	Early Startup Experience		
Wednesday, October 28	2:00 p.m. – 3:00 p.m.	Early Interactions with FDA: The Pre-submission Program		
	3:45 p.m. – 4:45 p.m.	Varian Medical Systems		



All events will take place in the Innovation Hub. On the virtual platform, navigation to the Innovation Hub can be found from the Main Lobby or via the Exhibit Hall.

With Pride and Admiration.

We applaud **Dr. Lisa A. Kachnic** on her most recent accomplishment as Chair of the Scientific Committee for the 2020 ASTRO Annual Meeting.

Lisa A. Kachnic, MD, FASTRO, is Chief of the Radiation Oncology Service at NewYork-Presbyterian/Columbia University Irving Medical Center, and Chu H. Chang Professor of Radiation Oncology and Chair of the Department of Radiation Oncology at Columbia University Vagelos College of Physicians and Surgeons.

One of the nation's leading radiation oncologists and a pioneer of new approaches to optimize the effectiveness of radiation therapy, Dr. Kachnic is widely recognized for transforming the standard of care for gastrointestinal cancers integrating novel radiation delivery techniques. Dr. Kachnic holds several clinical trial leadership positions in the National Cancer Institute and its cooperative group research bases, and currently serves as Executive Officer for Multi-Modality Research for the SWOG Cancer Research Network.

The faculties of Columbia University and Weill Cornell Medicine continue to make breakthrough contributions to the field of radiation oncology, including the latest approaches of radiotherapy in combination with immune-boosting therapies. Our radiation oncology departments are helping to shape the future of personalized cancer treatments through biological and genetic research coupled with applications of the most advanced technologies in the field.



#4 Hospital in the Nation

Ranked by U.S.News & World Report 2020-2021



ARRO Annual Seminar continued from page 1

Welcome on DEMAND 11:00 a.m. - 11:15 a.m.

ARRO-01 The Job Search and Interviewing in the Time of 11:15 a.m. - 12:00 p.m.

COVID presented by Beth Beadle, MD LIVE

ARRO-02 Job Search Panel moderated by Lisa Kachnic, MD, 12:15 p.m. - 1:30 p.m.

FASTRO onDEMAND

ARRO-03 ARRO Mentoring and Networking presentations by 1:45 p.m. - 3:15 p.m.

ASTRO Chair Theodore DeWeese, MD, FASTRO and

Charles R. Thomas Jr., MD ZOOM

Monday, October 26

Monday's programming includes presentations by Chelain Goodman, MD, PhD; Keynote speaker John Suh, MD, FASTRO; and a discussion moderated by Rahul Tendulkar, MD, featuring a panel of leaders in radiation oncology including Neha Vapiwala, MD; Emma Fields, MD; Louis Potters, MD, FASTRO; and Daniel Petereit, MD, FASTRO.

11:00 a.m. - 11:15 a.m. Welcome to Day 2

11:15 a.m. - 11:45 a.m. ARRO-04 Variation in Residency Resources: Results of an ARRO

Survey presented by Chelain Goodman, MD, PhD onDEMAND

ARRO-05 Keynote: Becoming an Effective Leader presented by 11:45 a.m. - 12:30 p.m.

John Suh, MD, FASTRO onDEMAND

ARRO-06 Preserving Radiation Oncology by Investing in 12:45 p.m. - 2:00 p.m.

> Training: A Panel Discussion moderated by Rahul Tendulkar with a panelists Neha Vapiwala, MD, Emma Fields, MD, Louis Potters, MD, FASTRO, and Daniel Petereit, MD, FASTRO

ARRO Poster Viewing with a Professor LIVE 3:45 p.m. - 5:15 p.m.

Tuesday, October 27

Tuesday's program includes a large focus on financial planning and planning for the future and features presentations by Kyle Russo, MD; Amar Rewari, MD, MBA; Trevor Royce, MD, MS, MPH, and Shauna Campbell, DO.

Welcome to Day 3 11:00 a.m. - 11:15 a.m.

ARRO-07 Financial Planning for the New Physician presented 11:15 a.m. - 12:00 p.m.

by Kyle Russo, MD onDEMAND

12:10 p.m. - 1:15 p.m. ARRO-08 Radiation Oncology Economics, Practice Valuation

and Well Qualified Private Practice Candidates presented by

Amar Rewari, MD, MBA LIVE

ARRO-09 Results of the Graduating Resident Survey presented 1:30 p.m. - 3:00 p.m.

by Shauna Campbell, DO, and Trevor Royce, MD, MS, MPH

onDEMAND

Wednesday, October 28

The ARRO Annual Seminar wraps up on Wednesday with a day dedicated to global health, diversity, equity and inclusion and welcomes this year's global health award recipients, radiation oncology global health experts and a panel with members of ASTRO's Committee on Health Equity, Diversity and Inclusion.

11:00 a.m. - 11:10 a.m. Welcome to Day 4 onDEMAND

ARRO-10 Global Health Scholars Presentations by Health Award 11:10 a.m. - 11:50 a.m.

Recipients Mutlay Sayan, MD, Ankit Agarwal, MD, MBA,

and Joshua Rodriguez-Lopez, MD onDEMAND

ARRO-11 Leaders in Global Health Panel LIVE 12:00 p.m. - 1:15 p.m.

1:30 p.m. - 2:40 p.m. ARRO-12 Diversity, Equity and Inclusion: Improving Cancer Care for All, panelists Cristina Chapman, MD, Curtiland Deville Jr., MD, Chelsea Pinix, MD, Raymond Mailhot Vega, MD, and

Malika Siker, MD SimuLive

Visit the ASTRO Annual Meeting Conference Planner and filter by the ARRO session track for a complete listing and details on each session of the ARRO Annual Seminar.

The ASTRO Career Center

The Premier Radiation Oncology Recruitment Tool!



This online career site offers employers and job seekers a targeted and easy-to-use resource for employment connections.

Connect today at

www.astro.org/careercenter

STREET TALK

What are you most looking forward to at this year's Annual **Meeting?**



This is rare, but I am honestly at a loss for words to express just how excited I am to hear both ASTRO 2020 Keynote speakers! Dr. Knaul is a powerhouse for women's health equity whom I have met through her global oncology efforts and Dr. Kendi will bring a much needed discussion to our members about race and social justice that might help us begin the work of

transforming the social systems running our departments and places of work. Kudos to the ASTRO committee members who chose these speakers!

> - Julianne M. Pollard, PhD MD Anderson Cancer Center



I anticipate the 2020 ASTRO Annual Meeting to be extremely educational. I'm particularly looking forward to the master courses, PRO programs and scientific sessions. I'm also looking forward to the Presidential Symposium — a salient topic that needs the radiation oncology community's focus and continuous efforts.

> - Maikel Botros, MD Blount Memorial Hospital



For our profession of radiation oncology, ASTRO is pivotal to learn about innovative research findings and advance our knowledge. I am most looking forward to the important Presidential Symposium sessions that will focus on global health and disparities as well as the Storytelling sessions, all of which will give a personalized and humanistic

perspective to this meeting. I relish in the opportunity to learn from colleagues about evolving trends, new viewpoints in patient management and new technologies. This year is bound to be very special and make us proud of what we do as a field.

> - Salma Jabbour, MD Rutgers Cancer Institute of New Jersey

STREET TALK


What are you most looking forward to at this year's Annual Meeting?



As a researcher, what excites me most about going to ASTRO this year is to learn about the great new discoveries scientists in our field are making. In particular, I am excited to hear about new work from the all-star panel of scientists including

Drs. Minn, Weischelbaum, Bakhoum and Sfeir, assembled by Dr. Pippa Cosper, for the session on downstream effects of cytosolic DNA and dsRNA sensing in cancer, which will help us understand mechanisms of radiation innate immune activation.

> - Ravi Patel, MD, PhD University of Pittsburgh



I am looking forward to pathbreaking research, innovative trials, thoughtful discussions, sharing knowledge and networking with colleagues "virtually" to improve the lives of the patients we serve.

- Najeeb Mohideen, MD, FASTRO Northwest Community Hospital



I am looking forward to engaging in dialogue with colleagues and learning about the latest radiation oncology research in ASTRO's first ever virtual Annual Meeting.

- Edina Wang, MD MedStar Georgetown University Hospital

Cancer Breakthroughs:

Takeaways from the **Major Oncology Meetings of 2020**

Saturday, October 24 – Tuesday, October 27

ASTRO debuted this session in Chicago last year, and this year we've reengineered it to bring you more exciting breakthroughs, over more days, from more societies. It is key to the field of oncology to collaborate and share information across all specialties, and we're excited to expand our list of organizations to share even more science to attendees. These presentations will be offered daily as Live sessions during the scheduled times shown below and will be recorded for later viewing. Each session will showcase top studies from 2020.

AACR/RRS Saturday, October 24, 3:30 p.m.– 4:30 p.m.		
ESTRO	Sunday, October 25, 3:15 p.m 4:15 p.m.	
ASCO/ASH	Monday, October 26, 12:00 p.m 1:00 p.m.	
RSNA/AAPM	Tuesday, October 27, 1:45 p.m. – 2:45 p.m.	

CORPORATE AMBASSADORS

ASTRO PROUDLY RECOGNIZES THE ONGOING COMMITMENT OF OUR CORPORATE AMBASSADORS FOR THEIR OUTSTANDING YEAR-ROUND LEADERSHIP AND PROMOTIONAL SUPPORT OF RADIATION ONCOLOGY.





























New Gender Equity Community opens in the ROhub

By Krisha Howell, MD; Shauna Campbell, DO; Jessica Schuster, MD; Laura Dawson, MD, FASTRO ROhub

ASTRO is pleased to announce the launch earlier this month of a new community, ASTRO's Gender Equity, on the ROhub.

As part of the message of the 62nd Annual Meeting, Global Oncology: Radiation Therapy in a Changing World, we realize many of the physical and ideological barriers once separating people in health care and in the workplace — geography, language, culture, time zones — have been diminished in part due to technology. ASTRO recognizes, however, that despite these technological advances, there are striking disparities which manifest throughout time and virtual space. At the same time, the COVID-19 pandemic has highlighted structural inequities in health care, with disparities in people marginalized by race, age, socioeconomic status and gender becoming more apparent and inhibiting the collective goals of our field. Among them, diverse challenges exist unique to women in health care and individuals stymied by gender stereotyping. During the pandemic, women and health care workers with caregiving responsibilities are having increasing domestic demands. Already, a widening gender gap in academic productivity during the pandemic is being seen.2

In purveying the future landscape of radiation oncology, ASTRO President Dr. Thomas Eichler acknowledged in 2019 that the greatest asset to our field is our members. This remains true in 2020. It is through our members that the ASTRO Gender Equity Community seeks to connect, provide resources and offer a platform for women and others interested in gender equity to exchange ideas within the field of radiation oncology.

The Gender Equity Community was conceived with the recognition that a smaller percentage of female medical students are choosing radiation oncology as their preferred career. Additionally, a paucity of radiation oncology leadership positions are currently occupied by women. ASTRO recognizes the value of becoming a more equitable, diverse and inclusive professional society. The objective of the Gender Equity Community on the ROhub is to designate this space as a resource for ASTRO members to safely pose questions, raise concerns and foster support to achieve the above goals. We hope it will also provide an opportunity for networking and mentorship. Within the first week of its rollout, the forum engaged in discussion about the persistently low matriculation of female medical students selecting radiation oncology and the need to have women in leadership roles to help address this disparity. Female leaders are needed to not only mentor medical students but

also to guide other females into leadership roles. Other apt discussion topics opened on the forum at this time include sharing individual stories and improving ASTRO member gender demographic data.

We are thrilled to have this virtual space to provide constructive discussion of these and related issues for a positive contribution to our physicians' careers and wellness.

How to Participate:

The Gender Equity Network openly welcomes all active ASTRO members. To enroll, however, a member must go to the ROhub page on the ASTRO website (rohub.astro.org):

- 1. Sign in at the top right corner button.
- From there, a menu will appear under the header space.
- Second from the left is "Communities."
- Select "All Communities" to see all communities open to you or currently enrolled in by you. Communities are organized alphabetically.
- Scroll to "Gender Equity Network/Community."
- At the far right of the row is a blue button that can be selected to

Enrolled members may post and read the other posts within the community. Prior to posting, the submitted comment will be reviewed by a moderator to ensure our society's professionalism is maintained and to confirm that no parties would individually be harmed by anything posted within the community. Submitted comments will be posted within 24 to 48 hours of submission.

REFERENCES

- Eichler TJ. Join us in 2020 for ASTRO's 62nd Annual Meeting in Miami Beach. ASTRO Daily News. 2019;2;Sept 15-16:16.
- Andersen JP, Nielsen MW, Simone NL, et al. Covid-19 medical papers have fewer women first authors than expected. ELife. 2020;9:e58807.

ASTRO 2020 UNRESTRICTED EDUCATIONAL GRANT **SUPPORTERS** Merck & Co., Inc. **Novartis** Novocure Pfizer



Best Cyclotron Systems

Best Cyclotron Systems offers a large family of cyclotron designs with a broad energy range from 1 MeV to 150 MeV that can be configured and optimized for different applications.



	1–3 MeV	Deuterons for materials analysis (Patent Pending)		
NEW Best Cyclotrons	70–150 MeV	For Proton Therapy (Patent Pending)		
	3–90 MeV	High current proton beams for neutron production and delivery (Patent Pending)		
Best 15p Cyclotron	15 MeV Proton only, capable of high current up to 1000 Micro Amps, for medical radioisotopes			
Best 20u/25p Cyclotrons	20, 25–15 MeV	0, 25–15 MeV Proton only, capable of high current up to 1000 Micro Amps, for medical radioisotopes		
Best 30u/35p Cyclotrons	30, 35–15 MeV	Proton only, capable of high current up to 1000 Micro Amps, for medical radioisotopes		
Best 70p Cyclotron	70–35 MeV	Proton only, capable of high current up to 1000 Micro Amps, for medical radioisotopes		
Rest 150n (volotron		For all Medical Treatments including Benign and Malignant Tumors for Neurological, Eye,		





First Century of Contributions of TeamBest Global in Healthcare Worldwide

A book to be published and distributed free of cost at the 2021 ASTRO Annual Meeting!

Best ABT Molecular Imaging

Best Particle Therapy


The BG-75 Best 7.5 MeV Cyclotron for in-house production of ¹⁸F-FDG and other biomarkers

Push button graphic interface

- Kit based chemistry
- Single or batch dose production
- Final dose delivery to syringe or vial (option)
- Automated quality control testing
- Integrated cyclotron and chemistry self-shielding
- Complete production lab in a 5 x 5 meter area



400 MeV ion Rapid Cycling Medical Synchrotron (iRCMS) for Proton-to-Carbon Heavy Ion Therapy



www.bestcyclotron.com • www.bestabt.com • www.bestproton.com BCS tel: 604 681 3327 • Best ABT tel: 865 982 0098 • BPT tel: 703 451 2378

ANNUAL MEETING How-to Guide for Users

Table of Contents

How to Access the Meeting	.25
Main Lobby & Engagement Features	.26
T.J. Eichler Theater	.27
Science Center	28

Poster Hall	29
Exhibit Hall and Exhibitor Booths	30
Innovation Hub and Networking Lounge	31
Help Desk/ASTRO Resource Center	32



How to Access the Meeting

WHAT ARE THE TECHNICAL REQUIREMENTS TO ACCESS THE VIRTUAL PLATFORM?

ASTRO recommends attendees use their desktop or laptop computers and Google Chrome for the best performance and experience. A high-speed internet connection is required.


Operating System	Processor	RAM	Internet Browser	Hardware	Media Playback	Internet Connection
 Window 10 Windows 8.1 + Pro Windows 7 Android 4.4+ Apple Max OS X 10.9+ Applie IOS 8.4+ 	• 1GHz	• 1GB	 Internet Explorer 9+ All recent versions of Google Chrome Safari 5.0+ Firefox 3.6+ iPhone/iPhad - Safari/iOS 5.1+ Android Phone/Tablet - OS 2.3 or higher, Chrome, Native BRowser 2.3+ Windows Tablet - IE 10+ 	Audio: Sound card with speakers Video: Screen with 1024x768+ resolution support	HTML 5 streaming enabled browser Apple iOS http streaming enabled browser Android http streaming enabled browser	Dedicated high speed connection of 900

HOW DO I LOG INTO THE VIRTUAL PLATFORM?

To access the virtual event, navigate to www.astro.org/AMnow. (China-based attendees should use this url: https://astro.6connex.com/event/virtual/login). Registrants will log in with the same email that was used to register for the meeting and the password will be the registration ID number (confirmation #). The registration confirmation number can be found on your confirmation email and by logging into your My ASTRO profile. Under the Green Product Catalog button, you will see your 2020 Annual Meeting Registration ID number. Registrants may also use the Forgot Password option on the log-in page.



Log in and click on the Entrance sign to enter the meeting.



Main Lobby and Engagement Features

From the lobby, you will navigate to the main areas of the meeting, including the T.J. Eichler Theater, Networking Lounge, Exhibit Hall and Poster Hall. Here and in every room, you will also find your navigation menu bar across the bottom of the screen, which will house your meeting briefcase, quick access to the ASTRO Resource Center and the chat features.



SEARCH BAR

Search for content site wide or search for attendees site wide or by location. You can also initiate a 1:1 chat



ATTENDEE LIST

Ability to view and search all online attendees or list of representatives and connect via chat. See how many are currently online and how many are in the same room as you.



CHAT

Available from both the bottom navigation and top navigation bars. Chat translation is available in many languages.

- Types of chat: Booth chat with a company representative, one-on-one and small group chat, or enter a chat queue.
- Ability to have up to 10 chats, 10 people max in each chat.
- Chat windows will appear in the lower right hand corner.



BREIFCASE


The Annual Meeting "briefcase" feature makes it easy to collect and store the content you want to save and share. You can save product information and marketing materials from the Exhibit Hall and more in your briefcase, then share those items with a colleague, as well as download and save them to your own device. ASTRO will upload Daily Highlights to provide a quick glance at the what's happening for the day. You will also find your meeting User Guide and the official ASTRO Daily News in the briefcase. Access your briefcase from the navigation bar found at the bottom of your screen.



LEADERBOARD


Welcome to the 2020 ASTRO Leaderboard Game! Here's how it works:


You will have an opportunity to gain points throughout the meeting for a chance to win one of our exciting prizes! You can collect points by adding materials to your briefcase, engaging in sessions, hanging out in the Exhibit Hall and more! The leaderboard will remain open from October 22, 2020, 12:00 a.m. ET to October 28, 2020 11:59 p.m. ET.



T.J. Eichler Theater

- Click to attend the Presidential Symposium, Keynotes, Special Sessions, including ticketed events, and the full educational program, including education sessions, panels, joint sessions, the PRO program, the ARRO program and more.
- When you click on the session types, a pop-up window will appear and look like this. A timer counts down until the session start or release time. Click the session in the list to join or view.





Science Center




The Science Center is where you will find the Scientific Sessions, Quick Pitch sessions, Science Highlights, Cancer Breakthroughs sessions and the Poster Hall.






Public chats are available in rooms, including the T. J. Eichler Theater, Poster Hall, ASTRO Resource Center, Science Center, Networking Lounge and Exhibit Hall. Attendees can utilize the public chat to communicate with all attendees in the room at once. During Live or SimuLive sessions, attendees will be able to directly chat with faculty and attendees and post questions during the scheduled Q&A panels.





Poster Hall

View narrated posters and contact poster presenters by finding them in the attendee list. Scheduled poster Q&A sessions are available here by track. When you click on a specific track, a pop up window will appear:







Select which poster you would like to view and click launch.



Click the arrow on the bottom navigation bar of the poster to begin narration.

POSTER TRACKS













Palliative Care



Survivorship

Patient Reported Outcomes/QoL/



Exhibit Hall and Exhibitor Booths



BOOTH ICONS

To enter any booth, simply click on that booth's sign. Mouse over the booth sign for additional information. Enter the sponsor's booth to chat with representatives one-on-one or as a group, view product information, download marketing materials, view product demonstrations and more.



NAVIGATION

Use this navigation button to browse through our Exhibit Hall.





BOOTH ITEMS

Booth chat with a representative.



Click the different screens in the booth to learn more about the products and to contact a company representative. Each booth will be populated with curated content from the exhibiting company. You can save booth content to your personal briefcase from the main navigation bar. From the briefcase, content can be easily shared with a colleague or downloaded and saved to your computer.



View a list of reps you can speak to or open the public chat.



Innovation Hub and Networking Lounge



INNOVATION HUB

The Innovation Hub is where you will find Industry-Expert Theaters, Industry Sattelite Symposia and newly added Main Stage Presentations and 15-minute Lunchtime Product Demonstrations from featured exhibitors.



NETWORKING LOUNGE


The Networking Lounge offers public and private chat options as well as scheduled discussion topics and follow-up Q&A sessions for the educational and scientific programs, curated in advance. The Networking Lounge is a space for attendees and sponsors to come together and chat. Think of it just like a real Networking Lounge, where you can make connections. You can also access the Career Fair from the Networking Lounge.




ASTRO VIRTUAL HAPPY HOUR

October 26, 2020 | 5:30 p.m. - 6:30 p.m. Eastern time

Just because we can't meet in person doesn't mean we can't network and enjoy our time together. Make plans to join us for our "Virtual Happy Hour" where you will have the opportunity to connect with your peers, network with industry, show your competitive side, learn and explore new things, but — most importantly — have fun!





Help Desk/ASTRO Resource Center



CONTENT SCREENS

- This serves as our **Ask ASTRO booth**, where you can ask ASTRO staff questions regarding membership, receive technical assistance with the mobile app or Conference Planner and more.
- Here's where you'll find **CE Central** and all you need to know about continuing education and maintenance of certification (MOC) requirements. Learn about the ASTRO Academy, how to evaluate the meeting, claim credits and obtain a certificate of attendance.
- Learn about **ASTRO's political action committee (PAC)** and how you can more fully participate in the political process. Get the most recent legislative updates and ensure radiation oncologists' voices are heard by key policymakers on Capitol Hill. For more information, visit www.astro.org/astropac.
- Discover timely information about ASTRO's quality programs: **APEx**® and **RO-ILS**®. Whether you are just beginning or currently working on implementing a plan, ASTRO has resources to help. For individualized assistance, we recommend emailing apexsupport@astro.org and roils@astro.org.
- Join ASTRO staff to learn about the latest updates concerning the **Radiation Oncology Alternative Payment Model** and the **Merit-based Incentive Payment System (MIPS)**. Contact mips@astro.org for one-on-one assistance.



CONTACT US

Chat, email or view ASTRO's key contacts.



NAVIGATE

Navigate to the Career Center, ROI Booth or the PubHub.



CHAT WITH AN ASTRO REPRESENTATIVE

Have questions? Chat with an ASTRO representative to get more information.



FOLLOW US ON SOCIAL MEDIA

Click on each individual social media icon to view our social media pages.



TECHNICAL SUPPORT

If you need technical assistance with the video presentations or the virtual environment, click on "Technical Support" in the footer below the main menu navigation at the bottom of your screen.

6connex is available 8:00 a.m.-4:00 p.m. ET during the live meeting, October 24-28, 2020, to answer your technical questions.

Best medical international

Blood/Research Irradiators, Medical Physics Instruments, Dosimetry Systems, Radiation Monitoring, Intravascular Brachytherapy...and more!
















First Century of Contributions
of TeamBest Global in
Healthcare Worldwide


A book to be published and distributed free of cost at the 2021 ASTRO Annual Meeting!












Best Medical International, Inc. 7643 Fullerton Road, Springfield, VA 22153 USA tel: 703 451 2378 800 336 4970 www.besttotalsolutions.com www.teambest.com

We are raising the bar in cancer care

Our world-class physicians are excited to be part of the GenesisCare team. Visit our booth in the exhibitor hall to find out more of the reasons why.



Do you want to join the GenesisCare team? Visit our booth or contact:

